Information Provided By:
Fly News Breaks for April 22, 2015
ACOR
Apr 22, 2015 | 07:19 EDT
Piper Jaffray assumed coverage of Acorda Therapeutics with a Neutral rating and lowered its price target for shares to $37 from $38. Piper sees a balanced risk/reward at current share levels given the clinical and regulatory risks associated with Acorda's pipeline and the uncertain duration of exclusivity for Ampyra for multiple sclerosis-related walking difficulties.
News For ACOR From the Last 2 Days
There are no results for your query ACOR